File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Profiles of HBV DNA, ALT, and HBeAg status after stopping lamivudine in patients with HBeAg seroconversion

TitleProfiles of HBV DNA, ALT, and HBeAg status after stopping lamivudine in patients with HBeAg seroconversion
Authors
Issue Date2007
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The 58th Annual Meeting of the American Association of the Study of Liver Diseases (AASLD), Boston, MA., 2-6 November 2007. In Hepatology, v. 46 suppl. S1, p. 678A, abstract no. 989 How to Cite?
AbstractAIM: To determine the virological and biochemical relapse rates in Chinese CHB patients with lamivudine-induced HBeAg seroconversion after stopping lamivudine therapy, and to identify significant viral or biochemical factors predictive of subsequent relapse. METHODS: All patients from all Hepatology Clinic with lamivudine-induced HBeAg seroconversion with subsequent cessation of lamivudine therapy were recruited. Liver biochemistry, HBeAg, anti-HBe, and serum HBV DNA by PCR (COBAS Taqman) was determined at the time of stopping lamivudine, at 3 months, 6 months, 1 year, and yearly thereafter. RESULTS: Twenty-two patients were included, of which 16(73%) were male with a median age of 32 years (range, 21-55). The median duration of follow-up was 104 months (range, 31-150). Six (27%) patients had undetectable HBV DNA by PCR at the time of stopping lamivudine treatment. In total, 7(32%) patients had subsequent flare (as defined by ALT >2x upper limit of normal), with associated virological rebound of HBV DNA (as defined by 1 log increase from time of stopping therapy). The cumulative incidence of flare at 5 years was 44%, all occurring before 25 months. There was no significant difference in the cumulative incidence of flares between those patients that continued lamivudine for 6-12 months, 1-2 years and over 2 years after HBeAg seroconversion (p=0.58). In patients who had normal ALT and undetectable HBV DNA, their cumulative incidence of flare was not significantly different to those that had detectable HBV DNA or abnormal ALT at time of stopping lamivudine (p=0.73). Two patients underwent HBeAg seroreversion at 5 and 10 months, with resulting flares. The cumulative incidence of HBeAg seroreversion after stopping lamivudine was 9% at 5 years. Fourteen (64%) patients underwent virological rebound, with a cumulative incidence of 82% at 4 years. There was no significant difference in the cumulative incidence of virological rebound in patients with undetectable HBV DNA at the time of stopping lamivudine therapy compared to those with detectable HBV DNA. Of those with virological rebound, 8(57%) had HBV DNA >105 copies/ml. Neither patient age or gender, genotype, presence of precore or core promoter mutations were significant factors in subsequent flare or virological rebound after stopping lamivudine therapy. CONCLUSION: Despite the high sustained HBeAg seroconversion (81%) after stopping lamivudine, HBV DNA rebound occurred in 64%, of which 57% had HBV DNA >105 copies/ml and 32% had ALT flares. Patients who had both normal ALT and undetectable HBV DNA by PCR at the time of stopping lamivudine therapy did not have a lower cumulative incidence of flares.
Persistent Identifierhttp://hdl.handle.net/10722/102147
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorFung, JYYen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorTanaka, Yen_HK
dc.contributor.authorMizokami, Men_HK
dc.contributor.authorYuen, JCHen_HK
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorYuen, RMFen_HK
dc.date.accessioned2010-09-25T20:18:56Z-
dc.date.available2010-09-25T20:18:56Z-
dc.date.issued2007en_HK
dc.identifier.citationThe 58th Annual Meeting of the American Association of the Study of Liver Diseases (AASLD), Boston, MA., 2-6 November 2007. In Hepatology, v. 46 suppl. S1, p. 678A, abstract no. 989en_HK
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/102147-
dc.description.abstractAIM: To determine the virological and biochemical relapse rates in Chinese CHB patients with lamivudine-induced HBeAg seroconversion after stopping lamivudine therapy, and to identify significant viral or biochemical factors predictive of subsequent relapse. METHODS: All patients from all Hepatology Clinic with lamivudine-induced HBeAg seroconversion with subsequent cessation of lamivudine therapy were recruited. Liver biochemistry, HBeAg, anti-HBe, and serum HBV DNA by PCR (COBAS Taqman) was determined at the time of stopping lamivudine, at 3 months, 6 months, 1 year, and yearly thereafter. RESULTS: Twenty-two patients were included, of which 16(73%) were male with a median age of 32 years (range, 21-55). The median duration of follow-up was 104 months (range, 31-150). Six (27%) patients had undetectable HBV DNA by PCR at the time of stopping lamivudine treatment. In total, 7(32%) patients had subsequent flare (as defined by ALT >2x upper limit of normal), with associated virological rebound of HBV DNA (as defined by 1 log increase from time of stopping therapy). The cumulative incidence of flare at 5 years was 44%, all occurring before 25 months. There was no significant difference in the cumulative incidence of flares between those patients that continued lamivudine for 6-12 months, 1-2 years and over 2 years after HBeAg seroconversion (p=0.58). In patients who had normal ALT and undetectable HBV DNA, their cumulative incidence of flare was not significantly different to those that had detectable HBV DNA or abnormal ALT at time of stopping lamivudine (p=0.73). Two patients underwent HBeAg seroreversion at 5 and 10 months, with resulting flares. The cumulative incidence of HBeAg seroreversion after stopping lamivudine was 9% at 5 years. Fourteen (64%) patients underwent virological rebound, with a cumulative incidence of 82% at 4 years. There was no significant difference in the cumulative incidence of virological rebound in patients with undetectable HBV DNA at the time of stopping lamivudine therapy compared to those with detectable HBV DNA. Of those with virological rebound, 8(57%) had HBV DNA >105 copies/ml. Neither patient age or gender, genotype, presence of precore or core promoter mutations were significant factors in subsequent flare or virological rebound after stopping lamivudine therapy. CONCLUSION: Despite the high sustained HBeAg seroconversion (81%) after stopping lamivudine, HBV DNA rebound occurred in 64%, of which 57% had HBV DNA >105 copies/ml and 32% had ALT flares. Patients who had both normal ALT and undetectable HBV DNA by PCR at the time of stopping lamivudine therapy did not have a lower cumulative incidence of flares.-
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatologyen_HK
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.-
dc.titleProfiles of HBV DNA, ALT, and HBeAg status after stopping lamivudine in patients with HBeAg seroconversionen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailFung, JYY: jfung@sicklehut.comen_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailYuen, JCH: jchyuen@HKUCC.hku.hken_HK
dc.identifier.emailWong, DKH: danywong@hku.hken_HK
dc.identifier.emailYuen, RMF: mfyuen@hkucc.hku.hken_HK
dc.identifier.authorityFung, JYY=rp00518en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityYuen, RMF=rp00479en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/hep.22020-
dc.identifier.hkuros145544en_HK
dc.identifier.hkuros152468-
dc.identifier.volume46-
dc.identifier.issuesuppl. S1-
dc.identifier.spage678A, abstract no. 989en_HK
dc.identifier.epage678A, abstract no. 989-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats